BioCryst Pharmaceuticals is trading at $9.80 (4.9%) up in pre-market as technical momentum extends a multi-week uptrend in the absence of fresh company news.
- The stock is currently trading near 60-day highs, though technical indicators show an overbought Relative Strength Index (RSI).
- There are no new earnings, guidance, or regulatory developments reported, suggesting the move is driven by traders leaning into the ongoing bullish trend.